Special Issue "Role of Nanoparticles in Vaccines and Pharmaceuticals"
A special issue of Vaccines (ISSN 2076-393X).
Deadline for manuscript submissions: closed (31 May 2023) | Viewed by 4488
Interests: nanotechnology (delivery systems); vaccines; pancreatic cancer; vascular disease; drug discoveries (xanthine oxidase inhibitors, myeloperoxidase inhibitors and ACE2 inhibitors)
Nanoparticles (NPs) are small in size, but they have a relatively large surface area-to-volume ratio for efficiently carrying and absorbing other substances such as drugs, proteins, or nucleic acids (RNA and DNA). NP delivery systems may protect the enclosed therapeutic nucleic acids (TNAs) or other materials from enzyme digestion and enhance cellular uptake, significantly increasing therapeutic efficacy. NPs could be accumulated in tumor tissues through the mechanism of the enhanced vascular permeability and retention (EPR) effect. Various chemicals such as natural or synthetic polymers, liposomes, dendrimers, cationic lipid materials, and peptides have been used for NP formation. Currently approved mRNA vaccines for COVID-19 were successfully produced with liposome-based NPs. NPs can become the active-targeting delivery system through conjugation of cell-specific ligands or antibodies, which allow the NP to bind specifically to the cell that has the complementary receptor or unique cell surface biomarkers. Therefore, we would like to encourage the submission to this Special Issue of papers on recent advances in NP-based delivery systems for any vaccines and pharmaceuticals, including basic science, translational, preclinical, and clinical research. Nanomedicine could have a major impact on the prevention, diagnosis, and treatment of many human diseases, such as cancers, infections, and cardiovascular diseases.
Prof. Dr. Johnny(Changyi) Chen
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- therapeutic nucleic acids
- drug delivery systems
- active-targeting delivery